Literature DB >> 19383378

Intercepting pelvic cancer in the distal fallopian tube: theories and realities.

Christopher P Crum1.   

Abstract

The pathogenesis of high-grade serous carcinoma of the ovary has come into sharper focus as closer attention has been paid to the earlier phases of this disease. The study of patients with BRCA mutation has been of particular value, in as much as the examination of prophylactic salpingo-oophorectomies will reveal an early cancer in approximately 5% of individuals. Recently studies have shown that about 80% of these early carcinomas originate in the distal fallopian tube. This review summarizes the recent data supporting the distal fallopian tube as an important site for serous carcinogenesis, stressing both the presence of a novel precursor (the p53 signature) and the application of this model to all women irrespective of BRCA status. The challenges and unmet needs unmasked by this paradigm shift in ovarian cancer research are discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19383378      PMCID: PMC2712215          DOI: 10.1016/j.molonc.2009.01.004

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  30 in total

1.  Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes.

Authors:  R R Barakat; M G Federici; P E Saigo; M E Robson; K Offit; J Boyd
Journal:  Cancer       Date:  2000-07-15       Impact factor: 6.860

2.  Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.

Authors:  Amy Finch; Patricia Shaw; Barry Rosen; Joan Murphy; Steven A Narod; Terence J Colgan
Journal:  Gynecol Oncol       Date:  2005-08-31       Impact factor: 5.482

3.  Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer.

Authors:  J M Piek; P J van Diest; R P Zweemer; J W Jansen; R J Poort-Keesom; F H Menko; J J Gille; A P Jongsma; G Pals; P Kenemans; R H Verheijen
Journal:  J Pathol       Date:  2001-11       Impact factor: 7.996

4.  Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation.

Authors:  R A Ambros; M E Sherman; C M Zahn; P Bitterman; R J Kurman
Journal:  Hum Pathol       Date:  1995-11       Impact factor: 3.466

5.  Overexpression and mutation of p53 in endometrial carcinoma.

Authors:  M F Kohler; A Berchuck; A M Davidoff; P A Humphrey; R K Dodge; J D Iglehart; J T Soper; D L Clarke-Pearson; R C Bast; J R Marks
Journal:  Cancer Res       Date:  1992-03-15       Impact factor: 12.701

6.  Serous carcinogenesis in the fallopian tube: a descriptive classification.

Authors:  Elke Jarboe; Ann Folkins; Marisa R Nucci; David Kindelberger; Ronny Drapkin; Alexander Miron; Yonghee Lee; Christopher P Crum
Journal:  Int J Gynecol Pathol       Date:  2008-01       Impact factor: 2.762

7.  A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.

Authors:  Ann K Folkins; Elke A Jarboe; Aasia Saleemuddin; Yonghee Lee; Michael J Callahan; Ronny Drapkin; Judy E Garber; Michael G Muto; Shelley Tworoger; Christopher P Crum
Journal:  Gynecol Oncol       Date:  2008-03-14       Impact factor: 5.482

Review 8.  Intercepting pelvic cancer in the distal fallopian tube: theories and realities.

Authors:  Christopher P Crum
Journal:  Mol Oncol       Date:  2009-02-03       Impact factor: 6.603

9.  Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.

Authors:  Jurgen M J Piek; Bas Torrenga; Brenda Hermsen; René H M Verheijen; Ronald P Zweemer; Johan J P Gille; Peter Kenemans; Paul J van Diest; Fred H Menko
Journal:  Fam Cancer       Date:  2003       Impact factor: 2.375

10.  Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention.

Authors:  Joseph W Carlson; Alexander Miron; Elke A Jarboe; Mana M Parast; Michelle S Hirsch; Yonghee Lee; Michael G Muto; David Kindelberger; Christopher P Crum
Journal:  J Clin Oncol       Date:  2008-09-01       Impact factor: 44.544

View more
  59 in total

1.  Telomere length and genetic variation in telomere maintenance genes in relation to ovarian cancer risk.

Authors:  Kathryn L Terry; Shelley S Tworoger; Allison F Vitonis; Jason Wong; Linda Titus-Ernstoff; Immaculata De Vivo; Daniel W Cramer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-01-20       Impact factor: 4.254

2.  A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.

Authors:  Elena Ratner; Lingeng Lu; Marta Boeke; Rachel Barnett; Sunitha Nallur; Lena J Chin; Cory Pelletier; Rachel Blitzblau; Renata Tassi; Trupti Paranjape; Pei Hui; Andrew K Godwin; Herbert Yu; Harvey Risch; Thomas Rutherford; Peter Schwartz; Alessandro Santin; Ellen Matloff; Daniel Zelterman; Frank J Slack; Joanne B Weidhaas
Journal:  Cancer Res       Date:  2010-07-20       Impact factor: 12.701

3.  Feasibility of Complete Salpingectomy Compared With Standard Postpartum Tubal Ligation at Cesarean Delivery: A Randomized Controlled Trial.

Authors:  Akila Subramaniam; Christina T Blanchard; Britt K Erickson; Jeff Szychowski; Charles A Leath; Joseph R Biggio; Warner K Huh
Journal:  Obstet Gynecol       Date:  2018-07       Impact factor: 7.661

4.  Recent progress in the diagnosis and treatment of ovarian cancer.

Authors:  Danijela Jelovac; Deborah K Armstrong
Journal:  CA Cancer J Clin       Date:  2011-04-26       Impact factor: 508.702

5.  Re: The Association Between Hysterectomy and Ovarian Cancer Risk: A Population-Based Record-Linkage Study.

Authors:  Paul J van Diest; Ronald P Zweemer; Jurgen M J Piek
Journal:  J Natl Cancer Inst       Date:  2019-12-01       Impact factor: 13.506

6.  Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.

Authors:  Dana M Roque; Stefania Bellone; Diana P English; Natalia Buza; Emiliano Cocco; Sara Gasparrini; Ileana Bortolomai; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Thomas J Rutherford; Peter E Schwartz; Alessandro D Santin
Journal:  Cancer       Date:  2013-04-12       Impact factor: 6.860

7.  Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics.

Authors:  Amy L Gross; Robert J Kurman; Russell Vang; Ie-Ming Shih; Kala Visvanathan
Journal:  J Oncol       Date:  2010-04-27       Impact factor: 4.375

Review 8.  Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors.

Authors:  S Avril
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

9.  Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel.

Authors:  Diana M Cittelly; Irina Dimitrova; Erin N Howe; Dawn R Cochrane; Annie Jean; Nicole S Spoelstra; Miriam D Post; Xian Lu; Russell R Broaddus; Monique A Spillman; Jennifer K Richer
Journal:  Mol Cancer Ther       Date:  2012-10-16       Impact factor: 6.261

10.  Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis.

Authors:  K Levanon; V Ng; H Y Piao; Yi Zhang; M C Chang; M H Roh; D W Kindelberger; M S Hirsch; C P Crum; J A Marto; R Drapkin
Journal:  Oncogene       Date:  2009-11-23       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.